<bill session="115" type="s" number="2476" updated="2019-11-15T22:00:30Z">
  <state datetime="2018-02-28">REFERRED</state>
  <status>
    <introduced datetime="2018-02-28"/>
  </status>
  <introduced datetime="2018-02-28"/>
  <titles>
    <title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure that valid generic drugs may enter the market.</title>
    <title type="short" as="introduced">Expanding Access to Low Cost Generic Drugs Act</title>
    <title type="short" as="introduced">Expanding Access to Low Cost Generic Drugs Act</title>
    <title type="display">Expanding Access to Low Cost Generic Drugs Act</title>
  </titles>
  <sponsor bioguide_id="S001203"/>
  <cosponsors/>
  <actions>
    <action datetime="2018-02-28">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2018-02-28" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSHR" name="Senate Health, Education, Labor, and Pensions" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="s" session="115" relation="unknown" number="3411"/>
    <bill type="h" session="115" relation="unknown" number="1776"/>
    <bill type="s" session="115" relation="unknown" number="771"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Government information and archives"/>
    <term name="Intellectual property"/>
    <term name="Marketing and advertising"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2018-02-28T05:00:00Z" status="Introduced in Senate">Expanding Access to Low Cost Generic Drugs Act

This bill amends the Federal Food, Drug, and Cosmetic Act to disqualify from receiving market exclusivity a generic drug manufacturer who enters into an agreement with the patent holder for a brand name drug to delay getting the generic drug approved or to delay marketing it.</summary>
  <committee-reports/>
</bill>
